nystatin-a1 and Intestinal-Diseases

The oral cavity and the oesophagus are the main sites of involvement in orointestinal candidosis. The clinical pictures of these manifestations are characterized. Involvement of the stomach as well as the small and large intestine is an exceedingly rare but possible manifestation. There are obviously no repeatedly occurring characteristical symptoms, neither have controlled studies confirmed such characteristics. Recently a discussion has arised-undoubtedly to a large extent influenced by public media-to explain a variety of in particular gastrointestinal symptoms as a consequence of an apparent "mycotic infection of the orointestinal tract" as "a new mass disease". These reports lack any scientific basis supported by experimental or clinical studies. There are similarities to the "candidiasis hypersensitivity syndrome" or "the yeast connection", the existence of which has been critically denied by experts. Corresponding references are given. The author realizes the necessity to oppose this public debate on a critical scientific basis and to answer open questions by controlled studies.

Topics: Antifungal Agents; Candidiasis; Candidiasis, Oral; Esophagitis; Humans; Intestinal Diseases; Nystatin; Stomach Diseases; Syndrome

The aim of this study was to evaluate the effectiveness of an alternative treatment in a form of recommended diet modification during and after conventional treatment with antifungals in patients with a chronic form of intestinal Candida overgrowth (ICOG).. The study included patients with ICOG divided in two subgroups: patients treated with nystatin and recommended diet regime (study group-SG) and the patients treated only with nystatin (control group-CG). After treatment, the mycological control examination and follow-up were performed two times: the first one within ten days after the completion of antifungal treatment, and the second one three months after the treatment initialization.. A total of 120 patients finished the study: 80 from the SG and 40 from the CG. At the first mycological control examination of SG patients stools, we noted satisfactory antifungal and symptomatic effect in 56 out of 80 (70.0%) patients and 29 out of 40 (72.5%) in CG, with no statistically significant difference. However, at the second control stool examination, significantly higher percent (85%) of cured patients was recorded after three months of the recommended diet comparing with CG-17 out of 40 (42.5%).. Results of this pilot study showed that patients who adhered to diet modification during and after treatment with nystatin had better outcomes of ICOG and strongly suggest the need for diet modification in these patients which recommendation could reduce excessive prescription of antifungals.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; Candidiasis; Feces; Female; Follow-Up Studies; Humans; Intestinal Diseases; Male; Middle Aged; Nystatin; Pilot Projects; Treatment Outcome; Young Adult

Topics: Amphotericin B; Antifungal Agents; Candidiasis; Erythema; Female; Humans; Intestinal Diseases; Male; Middle Aged; Nystatin

Topics: Candida; Candidiasis; Candidiasis, Cutaneous; Feces; Humans; Intestinal Diseases; Microbial Sensitivity Tests; Nystatin

Gastrointestinal Candida infection is more prevalent than previously recognized. It is most often seen in patients with underlying impairment of the immune system but may also occur in apparently normal individuals. Esophageal involvement is most common, presenting with odynophagia, dysphagia, or bleeding. Gastric Candida infection may cause diffuse mucosal involvement or focal invasion of benign gastric ulcers. Intestinal candidiasis is uncommon and poorly characterized. The diagnosis is usually established by visualizing the characteristic yeast or mycelial forms in endoscopic brushings and biopsies. Oral nystatin is effective therapy in many patients, but other antifungal agents may be needed in extensive or persistent disease, especially in immunocompromised patients.

Topics: Candidiasis; Deglutition Disorders; Diagnosis, Differential; Esophageal Diseases; Flucytosine; Humans; Imidazoles; Intestinal Diseases; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Nystatin; Polyenes; Stomach Diseases